trending Market Intelligence /marketintelligence/en/news-insights/trending/6gyasyvscgll6tekozwuyw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ligand closes $42.3M acquisition of UK-based biotechnology company

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Ligand closes $42.3M acquisition of UK-based biotechnology company

San Diego-based Ligand Pharmaceuticals Inc. completed the acquisition of U.K.-based drug discovery biotechnology company Vernalis PLC for about $42.3 million.

According to an Oct. 10 press release, the consideration paid to Vernalis shareholders was offset by about $32 million of net cash on hand at Vernalis.

The completion follows the approval of the acquisition by Vernalis shareholders. The acquisition gave Ligand access to eight partnered programs, including those in the respiratory, oncology and central nervous system sectors, as well as a 70-person research and development team based in Cambridge, U.K.

MTS Securities LLC and finnCap Ltd. served as financial advisers, while Latham Watkins LLP served as legal adviser to Ligand for the deal.